Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
July 17 2018 - 12:04PM
Edgar (US Regulatory)
|
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
|
SEC
FILE
NUMBER
000-52445
|
[ ]
Form 10-K [ ] Form 20-F [ ] Form 11-K
[X]
Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR
For
Period Ended: May 31, 2018
|
[ ]
|
Transition
Report on Form 10-K
|
|
[ ]
|
Transition
Report on Form 20-F
|
|
[ ]
|
Transition
Report on Form 11-K
|
|
[ ]
|
Transition
Report on Form 10-Q
|
|
[ ]
|
Transition
Report on Form N-SAR
|
For
the Transition Period Ended:
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein.
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART
I — REGISTRANT INFORMATION
PETLIFE
PHARMACEUTICALS, INC.
Full Name of Registrant
N/A
Former
Name if Applicable
8033
Sunset Boulevard
Address
of Principal Executive Office
(Street and Number)
Los
Angeles, CA 90046
City,
State, and Zip Code
PART
II — RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check box if appropriate)
|
(a)
|
The
reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
|
|
|
|
[X]
|
(b)
|
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR, or Form N-CSR,
or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject
quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be
filed on or before the fifth calendar day following the prescribed due date; and
|
|
|
|
|
(c)
|
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART
III — NARRATIVE
State
below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof,
could not be filed within the prescribed time period.
Management
of PetLife Pharmaceuticals, Inc. (the “Company”) was unable to fully obtain the information necessary to complete
the preparation of the Company’s financial statements for the Quarterly period ended May 31, 2018 and the review of these
financial statements by the Company’s auditors in time for filing. Such information is required in order to prepare a complete
filing. As a result of this delay, the Company is unable to file its Quarterly Report on Form 10-Q within the prescribed time
period without unreasonable effort or expense. The Company expects to file within the extension period.
PART
IV — OTHER INFORMATION
(1)
|
Name
and telephone number of person to contact regarding this notification
|
SEBASTIAN
SERRELL-WATTS
|
|
(424)
|
|
216-6807
|
(Name)
|
|
(Area
Code)
|
|
(Telephone
Number)
|
(2)
|
Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange
Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding
12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If answer is no, identify report(s).
|
|
|
|
[X]
Yes [ ] No
|
|
|
(3)
|
Is
it anticipated that any significant change in results of operations from the corresponding
period for the last fiscal year will be reflected by the earnings statements to be included
in the subject report or portion thereof?
|
|
|
|
[ ]
Yes [X] No
|
|
|
|
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made.
|
PETLIFE
PHARMACEUTICALS, INC.
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
July 16, 2018
|
By:
|
/s/
Sebastian Serrell-Watts
|
|
Name:
|
Sebastian Serrell-Watts
|
|
Title:
|
Chief Executive Officer
|
Petlife Pharmaceuticals (CE) (USOTC:PTLF)
Historical Stock Chart
From Jul 2024 to Aug 2024
Petlife Pharmaceuticals (CE) (USOTC:PTLF)
Historical Stock Chart
From Aug 2023 to Aug 2024